Saudi Arabia’s Stock Exchange Seeks Foreign Investors

Saudi Arabia’s stock exchange wants to lure more foreign investors and raise foreign ownership by 25 percent.

According to an interview in Bloomberg, Saudi’s stock market Chief Executive Al Hussan said it has some 120 registered Qualified Foreign Investors (QFI), and the exchange is currently reviewing 180 more applications for QFI.

“It will be great if one day our 49 percent foreign-investor limit is challenged, but ideally we will be satisfied if in the next two years or more we have about 20 to 25 percent foreign ownership in our markets. We are telling global investors that our markets are open and are consistently encouraging them to invest with us,” he said.

Tadawul is also preparing to host the IPO of Saudi Arabia’s oil giant Aramco in late 2018. Officials say that Aramco could be worth up to US$2 trillion, and listing 5 percent of it could fetch US$100 billion if the valuation is legitimate. 

“The Saudi stock exchange has a long track record of attracting successful IPOs,” Hussan said. “The question of timing and other matters with the Aramco listing lies with the issuer, but from our side we are prepared for it.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More